FOLH1 and neoplasm: In addition to targeting PSMA, exploring other alternative tumor antigens, such as PSCA, disintegrin and metalloproteinase 17 (ADAM17M) and delta-like ligand 3 (DDL3), may also be a future direction (93–95).